• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sex - a potential factor affecting immune checkpoint inhibitor therapy for cancers.

作者信息

Hu Wang, Qian Xinye, Wang Shuang, Gao Lu, Xu Jingyi, Yan Jun

机构信息

Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.

School of Clinical Medicine, Tsinghua University, Beijing, China.

出版信息

Front Immunol. 2022 Oct 18;13:1024112. doi: 10.3389/fimmu.2022.1024112. eCollection 2022.

DOI:10.3389/fimmu.2022.1024112
PMID:36330508
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9622749/
Abstract
摘要

相似文献

1
Sex - a potential factor affecting immune checkpoint inhibitor therapy for cancers.性别——影响癌症免疫检查点抑制剂治疗的一个潜在因素。
Front Immunol. 2022 Oct 18;13:1024112. doi: 10.3389/fimmu.2022.1024112. eCollection 2022.
2
Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy.免疫检查点阻断治疗引起的免疫相关不良事件的免疫病理学基础。
Immunol Med. 2022 Jun;45(2):108-118. doi: 10.1080/25785826.2021.1976942. Epub 2021 Sep 19.
3
Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy.免疫相关不良事件（irAEs）：对免疫检查点抑制剂治疗的影响
J Natl Compr Canc Netw. 2020 Sep;18(9):1287-1290. doi: 10.6004/jnccn.2020.7640.
4
Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy.评估免疫检查点抑制剂治疗后皮肤和非皮肤免疫相关不良事件的共现模式。
J Am Acad Dermatol. 2023 Jan;88(1):246-249. doi: 10.1016/j.jaad.2022.05.015. Epub 2022 May 13.
5
Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management.肾上腺功能不全：免疫检查点抑制剂和免疫相关不良事件管理。
Clin J Oncol Nurs. 2020 Jun 1;24(3):240-243. doi: 10.1188/20.CJON.240-243.
6
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.免疫检查点抑制剂相关性肺炎的临床诊断与治疗。
Thorac Cancer. 2020 Jan;11(1):191-197. doi: 10.1111/1759-7714.13240. Epub 2019 Nov 24.
7
Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy.将微小变化与重大结果联系起来：将微生物群纳入免疫疗法中的谨慎前景。
Int J Mol Sci. 2021 Jul 23;22(15):7900. doi: 10.3390/ijms22157900.
8
A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy.与免疫检查点抑制剂治疗相关的多种心脏不良事件
Intern Med. 2022 Jul 15;61(14):2099-2100. doi: 10.2169/internalmedicine.9018-21. Epub 2022 Mar 12.
9
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.免疫检查点抑制剂治疗临床试验中泌尿系统癌症患者的不良反应：协作性系统评价和荟萃分析。
Eur Urol. 2022 Apr;81(4):414-425. doi: 10.1016/j.eururo.2022.01.028. Epub 2022 Jan 31.
10
Management of immune checkpoint inhibitor-related adverse events: A review of case reports.免疫检查点抑制剂相关不良反应的管理：病例报告综述。
Thorac Cancer. 2020 Mar;11(3):498-504. doi: 10.1111/1759-7714.13315. Epub 2020 Jan 22.

引用本文的文献

1
Decoding sex differences in human immunity through systems immunology.通过系统免疫学解析人类免疫中的性别差异。
Oxf Open Immunol. 2025 Jul 4;6(1):iqaf006. doi: 10.1093/oxfimm/iqaf006. eCollection 2025.
2
Retrospective analysis of pembrolizumab-related adverse reactions and death outcomes based on the FAERS database.基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库对帕博利珠单抗相关不良反应和死亡结局的回顾性分析。
BMC Cancer. 2025 May 22;25(1):917. doi: 10.1186/s12885-025-14342-2.
3
Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy.在涉及免疫疗法的膀胱癌临床试验中研究患者特征。
J Clin Med. 2025 Jan 29;14(3):879. doi: 10.3390/jcm14030879.
4
Risk Factors Predicting Outcomes in Advanced Upper Gastrointestinal Cancers Treated With Immune Checkpoint Inhibitors.预测接受免疫检查点抑制剂治疗的晚期上消化道癌预后的风险因素
Gastroenterology Res. 2024 Dec;17(5-6):195-204. doi: 10.14740/gr1768. Epub 2024 Oct 2.
5
Impact of race, ethnicity, and social determinants on outcomes following immune checkpoint therapy.种族、民族和社会决定因素对免疫检查点治疗后结局的影响。
J Immunother Cancer. 2024 Oct 26;12(10):e010116. doi: 10.1136/jitc-2024-010116.
6
Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer.性别差异——胰腺癌动物模型中药物疗效测试的见解
Cancers (Basel). 2024 May 16;16(10):1901. doi: 10.3390/cancers16101901.
7
An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma.一种基于增强基因突变的模型，用于预测黑色素瘤患者免疫检查点抑制剂的疗效。
Front Oncol. 2023 Jan 17;12:1077477. doi: 10.3389/fonc.2022.1077477. eCollection 2022.

本文引用的文献

1
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.癌症临床试验中接受免疫治疗、靶向治疗或化疗的患者发生严重不良事件的风险的性别差异。
J Clin Oncol. 2022 May 1;40(13):1474-1486. doi: 10.1200/JCO.21.02377. Epub 2022 Feb 4.
2
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.在非转移性去势抵抗性前列腺癌男性中，恩扎卢胺联合雄激素剥夺治疗的生存获益一致：按年龄和地区划分的 PROSPER 亚组分析。
Eur J Cancer. 2021 Dec;159:237-246. doi: 10.1016/j.ejca.2021.10.015. Epub 2021 Nov 14.
3
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.抑制髓系细胞中的雌激素信号转导可增强黑色素瘤的肿瘤免疫。
J Clin Invest. 2021 Dec 1;131(23). doi: 10.1172/JCI151347.
4
Sex Differences in Immunity to Viral Infections.病毒感染中的性别差异。
Front Immunol. 2021 Aug 31;12:720952. doi: 10.3389/fimmu.2021.720952. eCollection 2021.
5
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.免疫检查点抑制剂在癌症治疗中的应用：临床影响及反应和耐药的机制。
Annu Rev Pathol. 2021 Jan 24;16:223-249. doi: 10.1146/annurev-pathol-042020-042741. Epub 2020 Nov 16.
6
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.新诊断转移性肾细胞癌患者的延迟细胞减少性肾切除术。
Eur Urol. 2020 Oct;78(4):615-623. doi: 10.1016/j.eururo.2020.04.038. Epub 2020 Apr 30.
7
Sex differences in cancer mechanisms.癌症机制中的性别差异。
Biol Sex Differ. 2020 Apr 15;11(1):17. doi: 10.1186/s13293-020-00291-x.
8
Sex-associated molecular differences for cancer immunotherapy.癌症免疫治疗的性别相关分子差异。
Nat Commun. 2020 Apr 14;11(1):1779. doi: 10.1038/s41467-020-15679-x.
9
Sex disparities in cancer.癌症中的性别差异。
Cancer Lett. 2019 Dec 1;466:35-38. doi: 10.1016/j.canlet.2019.08.017. Epub 2019 Sep 18.
10
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy.癌症免疫疗法疗效、生物标志物和治疗策略的性别差异。
Molecules. 2019 Sep 4;24(18):3214. doi: 10.3390/molecules24183214.